Biblio Discovery — Demo Discovery Service

41 results for "Hanefeld Markolf"

Showing 1–20 · 1.75 seconds · RSS

  1. Journal Article Full text

    Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes

    Hanefeld Markolf

    Cardiovascular Diabetology, Vol. 6 No. 1 · 2007 · English · DOAJ Scopus

    Abstract Dysglycaemic disease is one of the most important health issues facing the world in the 21st century. Patients with type 2 diabetes and individuals with prediabetes are at risk of developing macrovascular and microvascular complications. Long-term management strategies are therefore…

    Also available at: PubMed Central

  2. Journal Article Full text

    Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial

    Hanefeld, Markolf; Bramlage, Peter

    Curr Diab Rep · 2013 · English · PubMed Central

    There has been a recent shift from a uniform treatment targeting HbA1c to a patient centered approach due to disappointing results of intensified glucose control in mega-trials such as VADT, ADVANCE, and ACCORD. In addition, morbidity and mortality has been substantially reduced since the UKPDS…

  3. Journal Article Full text

    The Current and Potential Therapeutic Use of Metformin—The Good Old Drug

    Drzewoski, Józef; Hanefeld, Markolf

    Pharmaceuticals (Basel) · 2021 · English · PubMed Central

    Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become the medication with steadily increasing potential therapeutic indications. A broad spectrum of experimental and…

  4. Journal Article Full text

    Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases

    Scholz, Gerhard H.; Hanefeld, Markolf

    Visc Med · 2016 · English · PubMed Central

    BACKGROUND: Since 1981, we have used the term metabolic syndrome to describe an association of a dysregulation in lipid metabolism (high triglycerides, low high-density lipoprotein cholesterol, disturbed glucose homeostasis (enhanced fasting and/or prandial glucose), gout, and hypertension), with…

  5. Journal Article Full text

    Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review

    Hanefeld, Markolf; Duetting, Eva; Bramlage, Peter

    Cardiovasc Diabetol · 2013 · English · PubMed Central

    BACKGROUND: Hypoglycaemia has been associated with increased cardiovascular (CV) risk and mortality in a number of recent multicentre trials, but the mechanistic links driving this association remain ill defined. This review aims to summarize the available data on how hypoglycaemia may affect CV…

  6. Journal Article Full text

    Is Hyperglycemia a Cardiovascular Risk Factor?

    Pistrosch, Frank; Natali, Andrea; Hanefeld, Markolf

    Diabetes Care · 2011 · English · PubMed Central

  7. Journal Article Full text

    Self-Monitoring of Blood Glucose

    Schnell, Oliver; Hanefeld, Markolf; Monnier, Louis

    J Diabetes Sci Technol · 2014 · English · PubMed Central

    Evidence for the value of self-monitoring of blood glucose (SMBG) with regard to the achievement of treatment targets, detection of postprandial glucose excursions, and minimization of glycemic variability is increasing. In large clinical trials, SMBG is a key component for the optimization of…

  8. Journal Article Full text

    A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus

    Owens, David R.; Monnier, Louis; Hanefeld, Markolf

    Diabetes Obes Metab · 2017 · English · PubMed Central

    Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular (CV) comorbidities, with CV disease being the most common cause of death in adults with T2DM. Although glucocentric therapies may improve glycaemic control (as determined by glycated haemoglobin levels), evidence…

  9. Journal Article Full text

    High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone

    Pfützner, Andreas; Schöndorf, Thomas; Hanefeld, Markolf et al.

    J Diabetes Sci Technol · 2010 · English · PubMed Central

    Systemic inflammatory activity has turned out to play a key pathogenic role in vascular atherosclerosis, insulin resistance, and type 2 diabetes mellitus. Inflammatory biomarkers may therefore be a valuable tool for risk evaluation. Among them, the best evidence to date supports the use of…

  10. Journal Article Full text

    Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report

    Haider, Ahmad; Haider, Karim; Saad, Farid et al.

    SAGE Open Med Case Rep · 2019 · English · PubMed Central

    For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile…

  11. Journal Article Full text

    The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

    Hanefeld, Markolf; Traylor, Louise; Gao, Ling et al.

    Cardiovasc Diabetol · 2017 · English · PubMed Central

    BACKGROUND: Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic outcomes in people with T2D uncontrolled on…

  12. Journal Article Full text

    Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials

    Hanefeld, Markolf; Monnier, Louis; Schnell, Oliver et al.

    Diabetes Ther · 2016 · English · PubMed Central

    Dysglycemia results from a deficit in first-phase insulin secretion compounded by increased insulin insensitivity, exposing β cells to chronic hyperglycemia and excessive glycemic variability. Initiation of intensive insulin therapy at diagnosis of type 2 diabetes mellitus (T2DM) to achieve…

  13. Journal Article Full text

    Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update

    Hanefeld, Markolf; Fleischmann, Holger; Siegmund, Thorsten et al.

    Diabetes Ther · 2020 · English · PubMed Central

    Type 2 diabetes is characterised by chronic hyperglycaemia and variable degrees of insulin deficiency and resistance. Hyperglycaemia and elevated fatty acids exert harmful effects on β-cell function, regeneration and apoptosis (gluco-lipotoxicity). Furthermore, chronic hyperglycaemia triggers a…

  14. Journal Article Full text

    Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study

    Hanefeld, Markolf; Pfützner, Andreas; Forst, Thomas et al.

    Cardiovasc Diabetol · 2011 · English · PubMed Central

    BACKGROUND: We analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and their combination in patients with basal insulin treatment on biomarkers of CV risk. METHODS: In this double-blind, randomized, multicentre, active comparator controlled trial, 121 patients…

    Also available at: DOAJ

  15. Journal Article Full text

    Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study

    Hanefeld, Markolf; Koehler, Carsta; Gallo, Silvina et al.

    Cardiovasc Diabetol · 2007 · English · PubMed Central

    BACKGROUND: One of the major controversies surrounding the metabolic syndrome (MetS) in type 2 diabetes is whether its single components act synergistically as risk factors for atherosclerotic vascular disease (AVD). We aimed to answer this by evaluating the relationship, and its various…

  16. Journal Article Full text

    The metabolic vascular syndrome - guide to an individualized treatment

    Hanefeld, Markolf; Pistrosch, Frank; Bornstein, Stefan R. et al.

    Rev Endocr Metab Disord · 2016 · English · PubMed Central

    In ancient Greek medicine the concept of a distinct syndrome (going together) was used to label ‘a group of signs and symptoms’ that occur together and ‘characterize a particular abnormality and condition’. The (dys)metabolic syndrome is a common cluster of five pre-morbid metabolic-vascular risk…

  17. Journal Article Full text

    Differences in Glycemic Variability Between Normoglycemic and Prediabetic Subjects

    Hanefeld, Markolf; Sulk, Stefan; Helbig, Matthias et al.

    J Diabetes Sci Technol · 2014 · English · PubMed Central

    So far the criteria for NGT and abnormal glucose tolerance (AGT) are based on HbA1c and 75 g oGTT. We present data on GV and diurnal profiles in stratified cohorts with AGT versus controls. 28 NGT, 42 AGT (15 IGT, 11 IFG, 16 CGI) matched for age and BMI classified by 75 g oGTT underwent a CGM with…